References
- 1. Haque, M. U., Ferdiousi, N. & Sajon, S. R. (2016). Anticancer agents derived from plant and dietary sources: a review. International Journal of Pharmacognosy 32, 55–66.
- 2. Reedijk, J. (2009). Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design. Eur. J. Inorg. Chem. 10, 1303–1312.
- 3. Coluccia, M. & and Natile, G. (2007). Trans-platinum complexes in cancer therapy. Anti-Cancer Agents Med. Chem. 7, 111–123.
- 4. Wang, X. Y. & Guo, Z. J. (2008). Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents. Dalton Trans. 1521–1532.
- 5. Kapoor, L.D. (1990). Handbook of Ayurvedic Medicinal Plants, Boca Raton, Florida, CRC Press, 416–417.
- 6. Hassan, M, Watari H., Almaaty, A. A., Yusuke Ohba, Y. & Sakuragi, N. (2014). Apoptosis and Molecular Targeting Therapy in Cancer. BioMed Res. Int., Article ID 150845, 23 pp.
- 7. Olszewski, U. & Hamilton, G. (2010). A better platinum-based anticancer drug yet to come? Med. Chem. 10, 293–301.
- 8. Weiss, R. B. & Christian, M. C. (1993) New Cisplatin Analogues in Development. Drugs 46, 360–377
- 9. Ott, I. & Gust, R. (2007). Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Med. Chem. 7, 95–110.
- 10. Williams, R. (2011). Discontinued drugs in 2010: oncology drugs. Expert. Opin. Invest. Drugs 20, 1479–1496.
- 11. Van den Berg, J. H., Beijnen, J. H., Balm, A. J. M. & Schellens, J. H. M. (2006). Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat. Rev. 32, 390–397.
- 12. Pabla, N. & Dong, Z. (2008). Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73, 994–1007.
- 13. McWhinney, S. R., Goldberg, R. M. & McLeod, H. L. (2009). Platinum neurotoxicity pharmacogenetics. Mol. Cancer Ther. 8, 10–16.
- 14. Gómez-Ruiz, S., Maksimović-Ivanić, D., Mijatović, S. & Kaluđerović, G. N. (2012). On the Discovery, Biological Effects, and Use of Cisplatin and Metallocenes in Anticancer Chemotherapy. Bioinorg. Chem. Appl. article ID 140284, 1–14.
- 15. Kaluđerović, G. N. & Paschke, R. (2011). Anticancer metallotherapeutics in preclinical development. Curr. Med. Chem. 18, 4738–4752.10.2174/092986711797535308
- 16. Koberle, B., Tomicic, M. T., Usanova, S. & Kaina, B. (2010). Cisplatin resistance: preclinical findings and clinical implications. Biochim. Biophys. Acta 1806, 172–182.
- 17. Lakomska, I., Fandzloch, M., Muziol, T., Liz, T. & Jezierska, J. (2013). Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(III) complexes with bulky triazolopyrimidine ligands. Dalton Trans. 42, 6219–6226.
- 18. Matesans, A. I., Leitao, I. & Souza, P. (2013). Palladium(II) and platinum(II) bis(thiosemicarbazone) complexes of the 2,6-diacetylpyridine series with high cytotoxic activity in cisplatin resistant A2780cisR tumor cells and reduced toxicity. J. Inorg. Biochem. 125, 26−31.
- 19. Smolenski, P., Jaros, S. W., Pettinari, C., Lupidi, G., Quassinti, L., Bramucci, M., Vitali, L. A., Petrelli, D., Kochel, A. & Kirillow, A. M. (2013). New water-soluble polypyridine silver(I) derivatives of 1,3,5-triaza-7-phosphaadamantane (PTA) with significant antimicrobial and antiproliferative activities. Dalton Trans. 42, 6572−6581.
- 20. Bertrand, B., Bodio, E., Richard, P., Picquet, M., Gendre, P. L. & Casini, A. (2015) Gold(I) N-heterocyclic carbene complexes with an “activable” ester moiety: possible biological applications. J. Organomet. Chem. 775, 124–129.
- 21. Best, S. L. & Sadler, P. J. (1996) Gold drugs: mechanism of action and toxicity. Gold Bull. 29, 87–93.10.1007/BF03214741
- 22. Pantelić, N., Zmejkovski, B. B., Trifunović-Macedoljan, J., Savić, A., Stanković, D., Damjanović, A., Juranić, Z., Kaluđerović, G. N. & Sabo, T. J. (2013). Gold(III) complexes with esters of cyclohexyl-functionalized ethylenediamine-N,N’-diacetate. J. Inorg. Biochem. 128, 146–153.
- 23. Pantelić, N., Stanojković, T. P., Zmejkovski, B. B., Sabo, T. J. & Kaluđerović, G. N. (2015). In vitro anticancer activity of gold(III) complexes with some esters of (S,S)-ethylenediamine-N,N’-di-2-propanoic acid. Eur. J. Med. Chem. 90, 766–774.
- 24. Berners-Price, S. J. & Filipovska, A. (2011). Gold compounds as therapeutic agents for human diseases. Metallomics 3, 863–873.
- 25. Nardon, C. & D. Fregona, D. (2016). Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics. Curr. Top. Med. Chem. 16, 360–380.
- 26. Warżajtis, B., Glišić, B. Đ., Savić, N. D., Pavic, A., Vojnovic, S., Veselinović, A., Nikodinovic-Runic, J., Rychlewska, U. & Djuran, M. I. (2017). Mononuclear gold(III) complexes with l-histidinecontaining dipeptides: tuning the structural and biological properties by variation of the N-terminal amino acid and counter anion. Dalton Trans. 46(8), 2594–2608.
- 28. Berners-Price S. J. (2011). Gold-based therapeutic agents: a new perspective, in Bioinorganic Medicinal Chemistry, ed. E. Alessio, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. DOI:10.1002/9783527633104.ch710.1002/9783527633104.ch7
- 29. Abbate, F., Orioli, P., Bruni, B., Marson, G. & Messori, L. (2000). Crystal structure and solution chemistry of the cytotoxic complex 1,2-dichloro(o-phenanthroline) gold(III) chloride. Inorg. Chim. Acta 311, 1–5.
- 30. Bertrand, B. & and Casini, A. (2014). A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds. Dalton Trans. 43, 4209–4219.
- 31. Gabbiani, C., Casini, A. & Messori, L. (2007). Gold(III) compounds as anticancer drugs. Gold Bull. 40, 73–81.
- 32. Wang, Y., He, Q., Sun, R., Che, C. M. & Chiu, J. F. (2005). Gold porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res. 65, 11553–11564.
- 33. Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini A. & Messori, L. (2009). Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev. 253, 1692–1707.
- 34. Petrović, V., Petrović, S. Joksić, G., Savić, J., Čolović, M., Cinellu, M. A., Massai, L., Messori L. & Vasić, V. (2014). Inhibition of Na+/K+-ATPase and cytotoxicity of a few selected gold(III) complexes. J. Inorg. Biochem. 140, 228–235.
- 35. Pantelić, N., Stanković, D. M., Zmejkovski, B. B., Kaluđerović, G. N. & Sabo, T. J. (2016). Electrochemical properties of some gold(III) complexes with (S,S)-R2edda-type ligands. Int. J. Electrochem. Sci. 11, 1162–1171.
- 36. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63.10.1016/0022-1759(83)90303-4
- 37. Ohno, M. & Abe, T. (1991). Rapid colorimetric assay for the quantification of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6). J. Immunol. Methods 145, 199–203.